Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays.
Coronavirus disease 2019 (COVID-19)
Quantitative SARS-CoV-2 antibody assay
SARS-CoV-2 spike protein
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
10
06
2022
revised:
05
08
2022
accepted:
17
08
2022
pubmed:
28
8
2022
medline:
9
9
2022
entrez:
27
8
2022
Statut:
ppublish
Résumé
The concentration of antibodies against the SARS-CoV-2 spike protein is frequently being measured for clinical and epidemiological purposes. The aim of this study was to examine whether the results of different quantitative SARS-CoV-2 spike antibody assays are comparable. The Siemens SARS-CoV-2 IgG, Abbott SARS-CoV-2 IgG II Quant, Roche ElecsysT Anti-SARS-CoV-2 S, and Euroimmun Anti-SARS-CoV-2-QuantiVac assay were compared with 110 sera from patients 6-9 months after SARS-CoV-2 infection and the WHO First International SARS-CoV-2 antibody standard 20/136. The antibody values were converted into WHO binding antibody units (BAU)/ml. The diagnostic sensitivity of the assays was determined and the antibody values were compared. The diagnostic sensitivity ranged from 57.3% (Euroimmun) to 100% (Roche). The antibody concentration values of different assays correlated with Pearson coefficients of correlation between 0.729 and 0.953. The geometric mean antibody values of the Abbott, Siemens and Euroimmun assay varied by a factor of 1.1-1.2. The geometric mean antibody values of the Roche assay were 2.4-2.8 times higher than those from the other assays. The assays yielded varying results with the WHO International antibody standard. The quantitative SARS-CoV-2 antibody assays from Abbott, Siemens, Roche and Euroimmun correlate strongly but differ in the antibody concentrations. Therefore, the same assay should be used when testing patients repeatedly. In addition, the name of the assay used and the manufacturer should be indicated along with the test results.
Sections du résumé
BACKGROUND
The concentration of antibodies against the SARS-CoV-2 spike protein is frequently being measured for clinical and epidemiological purposes. The aim of this study was to examine whether the results of different quantitative SARS-CoV-2 spike antibody assays are comparable.
MATERIAL AND METHODS
The Siemens SARS-CoV-2 IgG, Abbott SARS-CoV-2 IgG II Quant, Roche ElecsysT Anti-SARS-CoV-2 S, and Euroimmun Anti-SARS-CoV-2-QuantiVac assay were compared with 110 sera from patients 6-9 months after SARS-CoV-2 infection and the WHO First International SARS-CoV-2 antibody standard 20/136. The antibody values were converted into WHO binding antibody units (BAU)/ml. The diagnostic sensitivity of the assays was determined and the antibody values were compared.
RESULTS
The diagnostic sensitivity ranged from 57.3% (Euroimmun) to 100% (Roche). The antibody concentration values of different assays correlated with Pearson coefficients of correlation between 0.729 and 0.953. The geometric mean antibody values of the Abbott, Siemens and Euroimmun assay varied by a factor of 1.1-1.2. The geometric mean antibody values of the Roche assay were 2.4-2.8 times higher than those from the other assays. The assays yielded varying results with the WHO International antibody standard.
CONCLUSIONS
The quantitative SARS-CoV-2 antibody assays from Abbott, Siemens, Roche and Euroimmun correlate strongly but differ in the antibody concentrations. Therefore, the same assay should be used when testing patients repeatedly. In addition, the name of the assay used and the manufacturer should be indicated along with the test results.
Identifiants
pubmed: 36029637
pii: S1386-6532(22)00201-3
doi: 10.1016/j.jcv.2022.105269
pmc: PMC9388276
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105269Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
J Clin Microbiol. 2022 Jan 19;60(1):e0174621
pubmed: 34705539
J Clin Microbiol. 2021 Aug 18;59(9):e0123121
pubmed: 34166066
Diagnostics (Basel). 2021 Aug 19;11(8):
pubmed: 34441430
Diagnosis (Berl). 2021 Dec 02;9(2):274-279
pubmed: 34851563
Microbiol Spectr. 2022 Feb 23;10(1):e0140221
pubmed: 35196824
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
J Infect Dis. 2022 Sep 4;226(4):664-672
pubmed: 35104869
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Vaccines (Basel). 2021 Jul 31;9(8):
pubmed: 34451965
Diagn Microbiol Infect Dis. 2022 Feb;102(2):115587
pubmed: 34826767
J Clin Microbiol. 2022 Feb 16;60(2):e0226221
pubmed: 34851700